A drug for treating diabetes similar to popular weight-loss medicines such as Ozempic did not show any benefits for people ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Popular GLP-1 medications like semaglutide and tirzepatide have been linked to rare vision issues, including NAION, raising ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.

1:52 Semaglutide associated with blindness risk ... that the FDA alert does not relate to the company’s products, Ozempic or Wegovy, but pertains to compounded semaglutide products, which ...